RAP1B, member of RAS oncogene familyGenealiases: K-REV · RAL1B · THC11
Q-omics provides the consensus-scored RAP1B profile across patient tissues and cancer cell-line models. RAP1B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RAP1B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RAP1B RNA expression shows 19,962 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where RAP1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAP1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAP1B survival associations across molecular data types. RAP1B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAP1B RNA expression–survival associations across cancer types. High RAP1B expression shows unfavorable associations in MESO, UVM, CESC, LGG, LIHC and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RAP1B RNA expression.
This table summarizes RAP1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RAP1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAP1B shows lower tumor expression in KICH, LUSC and THCA and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher RAP1B RNA expression in tumor versus normal tissue (log2 FC = +1.193, t-test p < 0.001).
This table shows molecular features associated with RAP1B in patient tissues and cancer cell lines. In patient samples, RAP1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAP1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
